Disclosed is the use of ivabradine also known as 3-{ 3-[{ [(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl} (methyl)amino]propyl} -7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms and perindopril also known as (2S,3aS,7aS)-1-[(2S)-2-{ [(2S)-1-ethoxy-1-oxopentan-2-yl]amino} propanoyl]-octahydro-1H-indole-2-carboxylic acid or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms, for the manufacture of a medicament for the treatment of heart failure with preserved systolic function.
